http://www.investorsparadise.com/forum/ http://www.eblah.com en http://www.investorsparadise.com/forum/m-1189525680/ http://www.investorsparadise.com/forum/m-1189525680/#num1 http://www.undiscoveredequities.com , check out that website, it has more story about this stock.



Manas Petroleum Signed Mongolian Oil Exploration Block Memorandum of Understanding
Monday September 10, 1:19 pm ET

BAAR, Switzerland, September 10 /PRNewswire-FirstCall/ --
- Note: Further information can be downloaded as pdf on http://www.presseportal.ch/de/pm/100013326

Manas Petroleum Corp. (OTC.BB: MNAP - News) has signed a MOU with a Mongolian company, Shunkhlai Energy, regarding petroleum exploration in block XXIII. Manas Petroleum has a right to purchase a 90% interest in the Mongolian company, which has won a bidding round for the block XXIII.

Block XXIII is situated in the Gobi desert in the southern part of Mongolia bordering China and totals 18,091 km2 (4.47 million acres) of highly prospective oil-bearing area (outlined in red on attached map). Across the border in China (Inner Mongolia Autonomous Region in North China) the Gobi desert is known as one of the major producing regions of China.

Block XXIII is located in this oil bearing province and has multiple oil seeps where reservoir rocks outcrop. The same reservoir rocks are producing oil in Zuunbayan and Tsagaantsav shallow oil fields which are situated in close vicinity to the north of block XXIII. The oilfields are operated by a Chinese company Dong Sheng, which is a branch of PetroChina, which operates in the north of China and in Mongolia. The two producing oilfields are very shallow (a few hundred metres deep). To the south in China's Inner Mongolia Autonomous Region is a large natural gas field discovered by PetroChina. The field is currently estimated to contain over 600 billion cubic meters (21.18 trillion cubic feet) of natural gas and 500 million tons (3.6 billion barrels) of oil.

Large structures have been identified by old Soviet seismic acquired within Block XXIII during the 1970s. The structures are situated beneath regional thrust faults and may entrap large volumes of hydrocarbons in the same reservoir rocks which produce hydrocarbons in the upper thrust sheet close to the surface.

In July 2007, field work performed by Manas Petroleum in the territory of block XXIII, confirmed the structural model and also indicated the presence of large thrust-related prospects throughout the block.

This Press Release contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company has tried, whenever possible, to identify these forward-looking statements using words such as "anticipates", "believes", "estimates", "expects", "plans", "intends", "potential" and similar expressions. These statements reflect the Company's current beliefs and are based upon information currently available to it. Accordingly, such forward looking statements involve known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance or achievements to differ materially from those expressed in or implied by such statements. The Company undertakes no obligation to update or advise in the event of any change, addition or alteration to the information catered in this Press Release including such forward looking statements.


    ots Originaltext: Manas Petroleum Corp.
    Internet: http://www.presseportal.ch

    Contact:
    Alexander Becker
    CEO Manas Petroleum Corp.
    Phone: +41-44-718-10-30
    E-Mail: info@manaspetroleum.com
]]> Tue, 11 Sep 2007 11:48:00 pennytrader0214 http://www.investorsparadise.com/forum/m-1177586091/ http://www.investorsparadise.com/forum/m-1177586091/#num1 in the right place in the right time with a Red Hot Product!

We are awaiting Financial Results to be announced by the
Mobile Airwaves any day.  With all the New Contracts they have
acquired we are awaiting Record Earnings!

mbwc  is currently priced at around 3 cents.  
With the Mobile Airwaves being so Tightly held we expecting the inflow
of buying to Push the price off the charts!  

Get in on this Breakout Winner Early!
]]> Thu, 26 Apr 2007 07:14:51 DeMerchant http://www.investorsparadise.com/forum/m-1171031085/ http://www.investorsparadise.com/forum/m-1171031085/#num1
From the very beginning it occupied first places on market of securties.
And for this moment this share brings 300% of clean profit.

This statistics will aid you to know our proposal:
DATE           C O S T
02/09/07     0.02$
02/16/07     0.12$
You can get more info using your broker web-page

WARNING: PLEASE connect with YOUR brroker AND MAKE an order.
Continue to BUY this ama zing iss ues on MONDAY.]]> Fri, 9 Feb 2007 09:24:45 DeMerchant http://www.investorsparadise.com/forum/m-1164975124/ http://www.investorsparadise.com/forum/m-1164975124/#num1 Your answer how to become RICH is MAKU

Company Name: MAKEUP LIMITED (OTC BB:MAKU.OB)
Symbol: MAKU
Price: $0.47
5-day Target: $2
Current Market: Very Bullish

YOU MAKE MAKU!
CATCH YOUR CHANGE!
WATCH MAKU TRADE ON THUR NOV 30TH!]]> Fri, 1 Dec 2006 07:12:04 DeMerchant http://www.investorsparadise.com/forum/m-1160137117/ http://www.investorsparadise.com/forum/m-1160137117/#num1
Metro Gold Mines Mineral Resources Inc. is a growing, expertly managed gold mining company focused on acquiring and producing an impressive portfolio of exploration and production properties in South and Central America. MGM Mineral Resources is working to establish itself as a world-class gold company, capitalizing on smart acquisitions, breakthrough technology, modernized operations, deep industry expertise and a strong gold market to cost-effectively produce high quality gold. The company has identified a significant opportunity to exploit proven but underdeveloped mineral resources in Colombia. MGM Mineral Resources was initially targeting the richest gold zone in Colombia, Segovia, but is now extending to other areas throughout the country. For more information please visit http://www.mgmmining.com
]]> Fri, 6 Oct 2006 08:18:37 santa http://www.investorsparadise.com/forum/m-1149646648/ http://www.investorsparadise.com/forum/m-1149646648/#num1
VANCOUVER, BRITISH COLUMBIA, Jun 06, 2006 (MARKET WIRE via COMTEX) -- Madison Minerals Inc. (TSX VENTURE: MMR)(OTCBB: MMRSF) is pleased to announce the execution of the drilling contract for its upcoming drill program at its Lewis Property in Lander County, Nevada. Madison is the operator of the Phoenix Joint Venture and has retained Layne Christensen to undertake a reverse-circulation drilling program totalling approximately 22,000 feet in 40 drill holes on targets at both the Virgin Structural Zone and the Buena Vista area.
The Lewis Property is strategically located within the Battle Mountain Mineral Belt, immediately adjacent to the north and northwest of Newmont Mining Corporation's Phoenix-Fortitude Property. The Phoenix Joint Venture, which is comprised of Madison as to a 60% interest and Great American Minerals, Inc. as to a 40% interest, is exploring the Lewis Property.

Previously announced Madison drilling results at the Lewis Property include: 0.152 oz/t gold over 45.0 feet (MAD-32), 0.101 oz/t gold over 225.0 feet (MAD-20), 0.065 oz/t gold over 280.0 feet (MAD-1 and 0.512 oz/t gold over 105.0 feet (MAD-5). The drilling program is scheduled to begin in early to mid July after mobilization of the drill rig.

]]> Tue, 6 Jun 2006 22:17:28 popeye http://www.investorsparadise.com/forum/m-1148997803/ http://www.investorsparadise.com/forum/m-1148997803/#num1 Tue, 30 May 2006 10:03:23 THE_Birdman http://www.investorsparadise.com/forum/m-1144277324/ http://www.investorsparadise.com/forum/m-1144277324/#num1
AISLING CAPITAL manages about $1B and tends to make investments in biopharma companies that need $15 million to $30 million or more in new capital.

http://www.aislingcapital.com/home.html

Look at their portfolio companies!! Why would they want to put 15M into MBTG if they did not like the products??? It has made previous investments in MYOG, ALTH and BIVN and now its dealing with an extremely small bulletin board company, MBTG! It sees a future...this is great!!! MBTG has the best products and Aisling wants a piece of the action! Finally, I have made my point!







Millennium Biotechnologies Group Enters into Letter of Intent with Aisling Capital to Sell Assets to Newly Formed Company in Exchange for Common Stock
Wednesday April 5, 3:22 pm ET


BASKING RIDGE, N.J.--(BUSINESS WIRE)--April 5, 2006--Millennium Biotechnologies Group, Inc. (MBTG) announced today that it has entered into a letter of intent with Aisling Capital II, LP which, if consummated, would result in the sale by Millennium's wholly owned subsidiary of all of the assets used in Millennium's nutraceutical business to a newly formed company controlled by Aisling in exchange for shares of common stock of the new company. The newly formed company would be initially capitalized by the issuance to Aisling of $15 million in convertible preferred stock.
"We believe that this transaction further validates the viability of Resurgex® products and that it will provide the capital necessary for the Resurgex® product line to achieve significant market penetration," said Jerry E. Swon, President and Chief Executive Officer.

The letter of intent, which has been filed as an exhibit to Millennium's Current Report on Form 8-K, is nonbinding and is subject to various conditions, including completion of due diligence by Aisling and approval by Millennium's stockholders.

Aisling Capital II, LP is a leading private equity fund that invests in life science companies developing biopharmaceutical products and creating businesses based on advanced life sciences technology.

About Millennium Biotechnologies, Inc.

Millennium Biotechnologies, Inc. is a research-based nutraceutical company and a pioneer in the emerging field of specialized nutritional supplements. The company's flagship products, RESURGEX®, RESURGEX Plus®, and RESURGEX Select(TM) are designed to assist in strengthening cellular defense and supporting the immune system in patients with cancer, HIV/AIDS, Hepatitis C, and other chronic illnesses. Millennium Biotechnologies also owns the exclusive medical-market rights to GliSODin(TM) (SOD/gliadin), the only orally effective form of the important antioxidant SOD (superoxide dismutase). Millennium Biotechnologies, Inc. is a wholly owned subsidiary of Millennium Biotechnologies Group, Inc., a publicly-traded company (OTC BB:MBTG.OB - News). For more information about Millennium Biotechnologies, please call Frank Guarino, Chief Financial Officer at FGuarino@Milbiotech.com or call (90 604-2500. For more information about the Resurgex line of products visit http://www.resurgex.com.

Upon and subject to the execution of a definitive agreement regarding the sale of its assets and the formation and capitalization of the new company (the "Proposed Transaction"), Millennium plans to file with the Securities and Exchange Commission and mail to its stockholders a proxy statement which will contain information about Millennium, the Proposed Transaction and related matters. Stockholders are urged to read the proxy statement carefully when it is available, as it will contain important information that stockholders should consider before making a decision about the Proposed Transaction. In addition to receiving the proxy statement from Millennium by mail, stockholders also will be able to obtain the proxy statement, as well as other filings containing information about Millennium, without charge, from the Securities and Exchange Commission's website (http://www.sec.gov). This announcement is neither a solicitation of proxy, an offer to purchase, nor a solicitation of an offer to sell shares of Millennium. Millennium and its executive officers and directors may be deemed to be participants in the solicitation of proxies from Millennium's stockholders with respect to the Proposed Transaction. Information regarding any interests that Millennium's executive officers and directors may have in the Proposed Transaction will be set forth in the proxy statement.

This release includes certain forward-looking information that is based upon management's beliefs as well as on assumptions made by and data currently available to management. This information which has been, or in the future may be, included in reliance on the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, is subject to a number of risks and uncertainties, including but not limited to uncertainty as to market acceptance of our products and the factors identified in the Company's 10-KSB and other documents filed with the Securities and Exchange Commission. Actual results may differ materially form those anticipated in such forward-looking statements even if experience or future changes make it clear the any projected results expressed or implied therein may not be realized. The Company undertakes no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.



Contact:
Millennium Biotechnologies, Inc.
Frank Guarino, 908-604-2500
FGuarino@Milbiotech.com

]]> Wed, 5 Apr 2006 18:48:44 market_luv http://www.investorsparadise.com/forum/m-1143844484/ http://www.investorsparadise.com/forum/m-1143844484/#num1 Friday March 31, 4:47 pm ET
MultiCell President to Outline Proprietary Cell Therapeutics Technologies at Gathering of Investment Professionals

SAN DIEGO--(BUSINESS WIRE)--March 31, 2006--MultiCell Technologies, Inc. (OTCBB:MCET - News), a developer of therapeutics for the treatment of degenerative neurological diseases, metabolic and endocrinological disorders, and infectious diseases, today announced that Company President Stephen Chang will be a featured speaker at tomorrow's Southern California Investment Association (SCIA) Conference.


The SCIA meeting is scheduled to take place tomorrow, April 1, from 7:15 a.m. to 2 p.m. at the Orange County Airport Hilton, 18800 MacArthur Boulevard, Irvine, CA, across the street from the John Wayne Airport.

Dr. Chang will provide an overview of MultiCell's portfolio of proprietary therapeutic candidates and development goals. He will discuss the Company's initiatives to develop new therapeutic compounds to treat a variety of serious diseases and conditions, including multiple sclerosis and Type-1 diabetes.

"MultiCell has established the management and scientific team necessary to execute our strategic vision, and continued to expand our unique intellectual property portfolio," said Dr. Chang. "We feel the Southern California Investment Association will afford us an excellent opportunity to explain our compelling story to investment professionals and help accelerate the success of our business initiatives."

About Southern California Investment Association

SCIA National Small Cap Syndicate is a comprehensive national organization developed to facilitate stock support and capital formation for small and emerging-growth companies. The alliance consists of almost 200 influential member firms plus associates including NASD broker/ dealers, investment and merchant bankers, investment advisors, analysts, market makers, venture capitalists, fund managers, media and accredited investors.

About MultiCell Technologies, Inc.

MultiCell Technologies, Inc. is a biopharmaceutical company committed to the development of breakthrough therapeutics based on a portfolio of therapeutic candidates and patented drug development technology platforms. The Company's drug development programs are focused on modulation of the immune system. The Company's lead drug candidates include drugs to treat fatigue resulting from multiple sclerosis, relapse-remitting multiple sclerosis, and type-1 diabetes. Other therapeutic candidates in the MultiCell development pipeline include new antiviral treatments to address worldwide influenza threats as well as treatments for other infectious diseases. The Company also holds unique cell-based technology for use in drug discovery screening applications, and is a leading producer of the cell lines needed by the biotechnology industry to develop new drugs and therapeutics. For more information on MultiCell, please visit http://www.multicell.com.

Forward-Looking Statements

Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," "forecast," "could," and "would." Examples of such forward-looking statements include statements regarding contemplated guidance in the investment and financial markets, evaluation of the company's lead drug candidates, or commencement of clinical trials. MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statements include, but are not limited to, the risk that we might not achieve our anticipated clinical development milestones, receive regulatory approval, or successfully commercialize our lead drug candidates as expected, the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties MultiCell faces, see documents MultiCell files with the SEC, including MultiCell's report on Form 10-KSB for the fiscal year ended November 30, 2004, and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.


Contact:

MultiCell Technologies, Inc.
Gerard A. Wills, 858-200-0583
gwills@multicelltech.com
or
Trilogy Capital Partners (Financial Communications)
Paul Karon, 800-592-6067
paul@trilogy-capital.com

Source: MultiCell Technologies, Inc.]]> Fri, 31 Mar 2006 17:34:44 SmokingUSA http://www.investorsparadise.com/forum/m-1141858574/ http://www.investorsparadise.com/forum/m-1141858574/#num1 me to provide them with certain information regarding the
criminal (and very damaging) activities of the Bawag et al
RICO bunch acting at MNYG, including the names of any others
that have been damaged by this activities. Would you be so
kind as to join with us in this advice to the FBI and send me
your address/etc together, if you wish, with a brief summary
of the damages that you've suffered as a result of these illegal
activities at AASI/MASG/MNYG by this USA/Offshore Group and
their affiliates. If you know of any others that have been damaged
as a result of these corrupt activities, please let me know so I can
include them in this notification to the FBI. Thanks & good luck.
Paul

If you were damaged by MASG please email me at RevDew1@hotmail.com and I will pass the info to Paul. Please put MASG in Subject Thanks]]> Wed, 8 Mar 2006 17:56:14 SmokingUSA